Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2111846 | 0.98 | FDPS (0.42) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| Water SCHEMBL921702 | 0.78 | FDPS (0.38) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| SCHEMBL240572 | 0.77 | FDPS (0.37) | FDPSCYP19A1 | |
| Water SCHEMBL2111842 | 0.76 | FDPS (0.36) | FDPSCYP19A1BTN3A1CA12GGPS1 | |
| SCHEMBL7245729 | 0.76 | FDPS (0.44) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| SCHEMBL2949292 | 0.74 | FDPS (0.47) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| SCHEMBL28888016 | 0.74 | FDPS (0.43) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| Phosphoric Acid SCHEMBL28121884 | 0.71 | FDPS (0.43) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| SCHEMBL21327739 | 0.70 | FDPS (0.43) | FDPSCYP19A1CYP17A1BTN3A1CA12 | |
| SCHEMBL28384395 | 0.70 | FDPS (0.47) | FDPSCYP19A1CYP17A1BTN3A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013685-A1 | Process for increasing the egg production and strengthening the eggshells of poultry | CEVA SANTE ANIMALE (FR) | 2003-01-16 | — | — | US | claimed |
| US-11013817-B2 | Nanoparticles for drug delivery to treat bone disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200121703-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION | 2020-04-23 | — | — | US | disclosed |
| US-20190307896-A1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | THE CLEVELAND CLINIC FOUNDATION | 2019-10-10 | — | — | US | disclosed |
| EP-3125884-A2 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of the University of Michigan (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016187544-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2015153959-A2 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-10-08 | — | — | WO | disclosed |
| US-9072757-B2 | Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins | UNIVERSITE D'AIX-MARSEILLE (FR) | 2015-07-07 | — | — | US | disclosed |
| US-20150105352-A1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | UNIVERSITÉ D'AIX-MARSEILLE (FR) | 2015-04-16 | — | — | US | disclosed |
| US-20130281408-A1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2013-10-24 | — | — | US | disclosed |
| US-20070021617-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021618-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021619-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20060178439-A1 | Crystalline form of zoledronic acid | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1612212-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | Teva Pharmaceutical Industries Ltd (IL) | 2006-01-04 | — | — | EP | disclosed |
| US-20050054616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICALS USA, INC. | 2005-03-10 | — | — | US | disclosed |
| CN-1481247-A | Use of zolendronate for mfg. medicament for treatment of bone metabolism diseases | 诺瓦提斯公司 | 2004-03-10 | — | — | CN | disclosed |
| US-6649601-B2 | Bisphosphonic compound | CEVA SANTE ANIMALE (FR) | 2003-11-18 | — | — | US | disclosed |
| US-20030013685-A1 | Process for increasing the egg production and strengthening the eggshells of poultry | CEVA SANTE ANIMALE (FR) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105352-A1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | GGPS1, HMGCR, FNTA | FDPS 4/4885CYP19A1 1506/4885CYP17A1 149/4885 |
| US-20130281408-A1 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS | GGPS1, HMGCR, FNTA | FDPS 4/4885CYP19A1 1506/4885CYP17A1 149/4885 |
| US-20030013685-A1 | Process for increasing the egg production and strengthening the eggshells of poultry | ALPP, FABP6, BMP6 | FDPS 298/4885CYP19A1 1370/4885CYP17A1 2880/4885 |
| US-20050054616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | SOST, FGF23, PTH1R | FDPS 905/4885CYP19A1 2150/4885CYP17A1 1385/4885 |
| US-20060178439-A1 | Crystalline form of zoledronic acid | FGF23, PTH1R, SOST | FDPS 1039/4885CYP19A1 820/4885CYP17A1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.